Optimization of Antitrypanosomatid Agents: Identification of Nonmutagenic Drug Candidates with in Vivo Activity

Citations Over TimeTop 10% of 2014 papers

Abstract

Chagas disease, caused by Trypanosoma cruzi parasite, was described thousands of years ago. Currently, it affects millions of people, mostly in Latin America, and there are not suitable drugs for treating it. As an attempt to find appropriate drugs to deal with this problem, we report here on the design, synthesis, and characterization of 82 new compounds. Trypanosomicidal behavior in vitro showed more than 20 outstanding derivatives with anti-Trypanosoma cruzi activity. Furthermore, we studied the nonspecific toxicity against mammalian cells determining their selectivity and also performed mutagenicity studies. Proof of concept, in vivo studies, was conducted with two of the most promising derivatives (77 and 80). They were identified as candidates because they have (i) very simple and cost-effective syntheses; (ii) activity against different stages and strains of the parasite showing excellent in vivo behavior during the acute phase of Chagas disease; and (iii) neither nonspecific toxicity nor mutagenic activity.

Related Papers

• → Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease(1987)497 cited
• → Antichagasic Activities of Natural Products against Trypanosoma cruzi(2009)36 cited
• → Buthionine Sulfoximine Has Anti- Trypanosoma cruzi Activity in a Murine Model of Acute Chagas' Disease and Enhances the Efficacy of Nifurtimox(2008)36 cited
• → Specific Treatment For Trypanosoma Cruzi Infection (Chagas Disease)(2003)28 cited
• → Rational Synthesis, Photophysical and Biochemical Evaluation of Fluorescents Chalcones as Inhibitors of Cruzain from Trypanosoma cruzi(2013)